Evaluation of public cancer datasets and signatures identifies TP53 mutant signatures with robust prognostic and predictive value

Table 4 A prognostic signature for patients with ER- breast cancer

ER negative dataset (sample size)	Clinical end points	Log-rank test	Univariate HR		Multivariate HR
		P value	HR (95% CI low-high)	P value	HR (95% CI low-high)	P value
BR1141(40)	RFS	0.828	1.1(0.4-3.0)	0.828	NA^#	NA
BR2411(69)	RFS	0.590	1.3(0.5-2.9)	0.591	NA	NA
BRGSE20624(115)	RFS	0.442	1.3(0.5-3.0)	0.602	NA	NA
BR25055(131)	DRFS	0.406	1.3(0.7-2.5)	0.406	NA	NA
BR1405(77)	RFS	0.015	2.5(1.2-5.4)	0.015	NA	NA
BRGSE21653(113)	DFS	0.022	2.1(1.1-3.9)	0.022	2.5(1.1-5.4)	0.023
BRMetabric	DSS	0.001	2.2(1.4-3.7)	0.001	2.4(1.1-5.2)	0.022
D22522925(196)	DSS	0.001	2.2(1.4-3.7)	0.001	2.4(1.1-5.2)	0.022
BRMetabric	DSS	0.015	1.6(1.1 -2.5)	0.015	1.7(1.0-2.9)	0.036
V22522925(244)	DSS	0.015	1.6(1.1 -2.5)	0.015	1.7(1.0-2.9)	0.036
BRTCGA(118)	OS	0.003	13.8(1.4-34.6)	0.003	3.2(1.5-5.2)	0.025

Note: Multivariate HR adjusted factors in each test dataset are as follows: BRGSE21653 (grade, PR, HER2 status, ki67), BRMetabricD22522925 and BRMetabricV22522925 (age, menopausal status, grade, size, stage, lymph node positivity, NPI, HER2 status, PAM50 subtype, treatment), BRTCGA (PR, HER2 status, T stage).
#: No adjusted clinical covariates; no mulitvariate HR analysis was performed.

ISSN: 1471-2407